Role of LAP positive immune cells in glioblastoma pathogenesis

LAP阳性免疫细胞在胶质母细胞瘤发病机制中的作用

基本信息

  • 批准号:
    8807222
  • 负责人:
  • 金额:
    $ 26.54万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2014
  • 资助国家:
    美国
  • 起止时间:
    2014-09-30 至 2016-08-31
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (provided by applicant): The suppression of the immune system is one of the major obstacles in the treatment of glioblastoma (GBM). Regulatory immune cells, such as FoxP3+ T lymphocytes and suppressive myeloid cells play a significant role in this process. LAP+ CD4+ T lymphocytes were recently described as superior regulatory cells in colorectal cancer and we found that other LAP+ immune cells may also have regulatory functions. Latency-associated peptide (LAP) is a derivative of the TGF-β gene and TGF-β is strongly implicated in GBM pathogenesis. Based on TCGA (The Cancer Genome Atlas) data, we found that TGF-β mRNA expression negatively correlates with human patient survival. We also found that different LAP+ immune cells infiltrate intracranial GBM, including subsets of both αβ and γδ+ T cells, macrophages and dendritic cells in a mouse model. Treatment of mice bearing sub-cutaneous GBM with anti-LAP antibodies led to elimination of GBM growth and was associated with a reduction of FoxP3+ and LAP+ T cells and up-regulation of the Th1 and cytotoxic T cell responses. Based on these observations, we hypothesize that cells expressing LAP suppress GBM-specific immunity and neutralization with anti-LAP antibodies will activate a tumoricidal immune response. In this project, we propose to study the role of neutralizing antibodies against LAP in overcoming the immunosuppression associated with GBM. Our specific aims are: Specific Aim 1: Investigate the immunosuppressive role of LAP in GBM. We propose to 1) determine the levels of LAP expression on immune cells in normal and GBM conditions in mouse and human; 2) define the phenotype of LAP+ immune cells infiltrating intracranial GBM isolated at different stages of disease progression in mouse and human; 3) perform functional analysis of LAP+ regulatory immune cells isolated from intracranial GBM. Specific Aim 2: Evaluate the therapeutic potential of anti-LAP antibodies in the treatment of a GBM intracranial mouse model. We propose to 1) characterize the effects of anti-LAP antibodies on the immune response in naive mice and mice bearing intracranial GBM; 2) assess the therapeutic value of anti-LAP antibodies in the experimental GBM models.
描述(由申请人提供):免疫系统的抑制是胶质母细胞瘤(GBM)治疗的主要障碍之一。调节性免疫细胞,如FoxP 3 + T淋巴细胞和抑制性骨髓细胞在这一过程中发挥重要作用。近年来,研究发现大肠癌中的上级调节细胞是CD 4 + T淋巴细胞,其他CD 4+免疫细胞也可能具有调节功能。潜伏相关肽(Latency-associated peptide,TGF-β)是TGF-β基因的衍生物,TGF-β与GBM的发病机制密切相关。基于TCGA(癌症基因组图谱)数据,我们发现TGF-β mRNA表达与人类患者生存率呈负相关。我们还发现,不同的α β +免疫细胞浸润颅内GBM,包括αβ和α β亚群, 小鼠模型中的γδ+ T细胞、巨噬细胞和树突状细胞。用抗CD 4抗体治疗皮下GBM小鼠导致GBM生长的消除,并与FoxP 3+和CD 4 + T细胞的减少以及Th 1和细胞毒性T细胞应答的上调相关。基于这些观察结果,我们假设表达LAP的细胞抑制GBM特异性免疫,并且抗LAP抗体的中和将激活杀肿瘤免疫反应。在这个项目中,我们建议研究抗GBM中和抗体在克服GBM相关免疫抑制中的作用。我们的具体目标是:具体目标1:研究LAP在GBM中的免疫抑制作用。我们建议1)确定小鼠和人在正常和GBM条件下免疫细胞上的IFN-γ表达水平; 2)定义在小鼠和人疾病进展的不同阶段分离的浸润颅内GBM的IFN-γ +免疫细胞的表型; 3)对从颅内GBM分离的IFN-γ +调节性免疫细胞进行功能分析。具体目的2:评价抗-GBM抗体在治疗GBM颅内小鼠模型中的治疗潜力。我们建议1)在幼稚小鼠和携带颅内GBM的小鼠中表征抗-β-内酰胺酶抗体对免疫应答的影响; 2)在实验GBM模型中评估抗-β-内酰胺酶抗体的治疗价值。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(2)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Howard L Weiner其他文献

Inducing tolerance one antigen at a time
一次诱导一种抗原的耐受性
  • DOI:
    10.1038/nbt.3573
  • 发表时间:
    2016-05-06
  • 期刊:
  • 影响因子:
    41.700
  • 作者:
    Rafael M Rezende;Howard L Weiner
  • 通讯作者:
    Howard L Weiner
Gamma-delta T cells suppress microbial metabolites that activate striatal neurons and induce repetitive/compulsive behavior in mice
γ-δ T 细胞抑制激活纹状体神经元并诱导小鼠重复/强迫行为的微生物代谢物
  • DOI:
    10.1016/j.bbi.2024.01.214
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Laura M Cox;Bruna K. Tatematsu;Lydia Guo;Danielle S LeServe;Julia Mayrink;Marilia G. Oliveira;Dustin Donnelly;Roberta C. Fonseca;Luisa Lemos;Toby B Lanser;Ana C. Rosa;Juliana R Lopes;Luke A Schwerdtfeger;Gabriela F.C. Ribeiro;Eduardo. L. C. Lobo;Thais G. Moreira;Andre G. Oliveira;Howard L Weiner;R. Rezende
  • 通讯作者:
    R. Rezende
Dietary protein modulates intestinal dendritic cells to establish mucosal homeostasis.
膳食蛋白质调节肠道树突状细胞以建立粘膜稳态。
  • DOI:
  • 发表时间:
    2024
  • 期刊:
  • 影响因子:
    8
  • 作者:
    Thais G. Moreira;Laura M Cox;Patrick da Silva;D. Mangani;Marilia G. DE OLIVEIRA;Giulia Escobar;Toby B Lanser;Liam Murphy;Eduardo. L. C. Lobo;Omer Milstein;Christian D. Gauthier;Ana CLARA GUIMARĀES;Luke A Schwerdtfeger;Mellicient N. Ekwudo;Caroline Wasén;Shirong Liu;Gustavo Menezes;Enio Ferreira;Galina Gabriely;Ana C Anderson;Ana MARIA C. FARIA;R. Rezende;Howard L Weiner
  • 通讯作者:
    Howard L Weiner
Accuracy of serum neurofilament light to identify contrast-enhancing lesions in multiple sclerosis
血清神经丝光识别多发性硬化症对比增强病变的准确性
  • DOI:
    10.1177/13524585231198751
  • 发表时间:
    2023
  • 期刊:
  • 影响因子:
    5.8
  • 作者:
    Gauruv Bose;B. Healy;Christian Barro;Vanessa F Moreira Ferreira;S. Saxena;B. Glanz;H. Lokhande;Mariann Polgar;R. Bakshi;Howard L Weiner;T. Chitnis
  • 通讯作者:
    T. Chitnis
Humoral response to COVID-19 vaccination in MS patients on disease modifying therapy: Immune profiles and clinical outcomes Multiple Sclerosis and Related Disorders
接受疾病修饰治疗的多发性硬化症患者对 COVID-19 疫苗接种的体液反应:免疫特征和临床结果 多发性硬化症和相关疾病
  • DOI:
  • 发表时间:
    2022
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Howard L Weiner;T. Chitnis
  • 通讯作者:
    T. Chitnis

Howard L Weiner的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Howard L Weiner', 18)}}的其他基金

Functional and Transcriptional Profiling of Monocytes in Alzheimer's Disease
阿尔茨海默病中单核细胞的功能和转录谱
  • 批准号:
    10370121
  • 财政年份:
    2022
  • 资助金额:
    $ 26.54万
  • 项目类别:
Role of the Intestinal Microbiota in ALS
肠道菌群在 ALS 中的作用
  • 批准号:
    10562004
  • 财政年份:
    2021
  • 资助金额:
    $ 26.54万
  • 项目类别:
Role of the Intestinal Microbiota in ALS
肠道菌群在 ALS 中的作用
  • 批准号:
    10328959
  • 财政年份:
    2021
  • 资助金额:
    $ 26.54万
  • 项目类别:
Role of the Intestinal Microbiota in ALS
肠道菌群在 ALS 中的作用
  • 批准号:
    10554437
  • 财政年份:
    2021
  • 资助金额:
    $ 26.54万
  • 项目类别:
Role of the Intestinal Microbiota in ALS
肠道菌群在 ALS 中的作用
  • 批准号:
    10755404
  • 财政年份:
    2021
  • 资助金额:
    $ 26.54万
  • 项目类别:
Targeting CNS neuroinflammation in animal models of Alzheimer's disease
靶向阿尔茨海默病动物模型中的中枢神经系统神经炎症
  • 批准号:
    9896439
  • 财政年份:
    2020
  • 资助金额:
    $ 26.54万
  • 项目类别:
Gut Microbiota in Patients with Multiple Sclerosis
多发性硬化症患者的肠道微生物群
  • 批准号:
    9333436
  • 财政年份:
    2014
  • 资助金额:
    $ 26.54万
  • 项目类别:
Circulating MicroRNAs as Disease Biomarkers in Multiple Sclerosis
循环 MicroRNA 作为多发性硬化症的疾病生物标志物
  • 批准号:
    9334952
  • 财政年份:
    2013
  • 资助金额:
    $ 26.54万
  • 项目类别:
Circulating MicroRNAs as Disease Biomarkers in Multiple Sclerosis
循环 MicroRNA 作为多发性硬化症的疾病生物标志物
  • 批准号:
    8581950
  • 财政年份:
    2013
  • 资助金额:
    $ 26.54万
  • 项目类别:
Transcriptional Control of Autoimmunity in the Central Nervous System
中枢神经系统自身免疫的转录控制
  • 批准号:
    8788961
  • 财政年份:
    2012
  • 资助金额:
    $ 26.54万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了